In pancreatic cancer, a proteomic study using gemcitabine-sensitive KLM1 and -resistant KLM1-R cells showed that PRDX2 was significantly up-regulated in KLM1-R cells [19]. Here, PRDX2 is linked to familial pancreatic carcinoma.